CaP化疗及新型药物治疗.pptVIP

Secondary Endpoints Presented By Christopher Sweeney at 2014 ASCO Annual Meeting Therapy beyond progression Presented By Christopher Sweeney at 2014 ASCO Annual Meeting Chemotherapy Doses Given Presented By Christopher Sweeney at 2014 ASCO Annual Meeting Non-Hematologic Toxicity (%) Presented By Christopher Sweeney at 2014 ASCO Annual Meeting Hematologic Toxicity (%) Presented By Christopher Sweeney at 2014 ASCO Annual Meeting Patrick-Miller LJ, et al. 2016 ASCO Abstract 5004. CHAARTED研究生活质量(QoL)分析—— 转移性激素敏感性前列腺癌化疗联合ADT的随机研究(E3805) A组和B组之间的差异 估值 SE P值 基线 -1.00 1.28 0.43 3个月 -3.09 1.32 0.02 6个月 0.90 1.34 0.50 9个月 0.29 1.37 0.84 12个月 2.85 1.39 0.04 FACT-P ADT+多西他赛 1.20 1.14 1.16 1.18 0 3 6 9 12 时间 (月) 总体FACT-P 仅ADT P=0.02 N=706 P0.01 N=548 ADT+多西他赛 vs 仅ADT 在3个月时总体QoL较差(90%RR) 在6个月时无差异 在12个月时更优(69%RR) 总体QoL：FACT-P(癌症治疗功能评价-前列腺癌)：总体及疾病特异性生活质量的自我报告评估。分数越高，说明QoL越好。 5个分量表如下 身体方面：躯体症状 社会方面：家庭及朋友关系 情感方面：抑郁、焦虑及应对方式 功能状况：做想要做的事的能力 针对前列腺癌的特定担忧：失禁、男性特征 研究结果：总体QoL（主要终点） Patrick-Miller LJ, et al. 2016 ASCO Abstract 5004. *校准年龄(≤59 vs. 60-69 vs. ≥70)、疾病严重程度(高 vs. 低)、局部治疗(是 vs. 否)、 ECOG PS(0 vs. 1/2)、基线身体状况(≤20 vs.20~25 vs. 25)及基线疼痛评分(0/1 vs. 2/3 vs. ≥4) FACT-F(乏力) FACT-紫杉类 情感状况 疼痛 结果证实接受ADT+多西他赛治疗的患者多项生活质量指标（情感状况，乏力）在12个月以后优于仅接受ADT患者 Patrick-Miller LJ, et al. 2016 ASCO Abstract 5004. 研究结果：次要终点 小结 多西他赛联合ADT治疗转移性激素敏感性前列腺癌可较单用ADT延长总生存13.6个月；对于高瘤负荷患者可以提高OS 17个月 接受ADT+多西他赛治疗的患者总体QoL(FACT-P)会暂时下降，但在治疗过程中逐渐恢复到基线水平，且在12个月以后优于仅接受ADT患者 Patrick-Miller LJ, et al. 2016 ASCO Abstract 5004. Slide 1 Presented By Nicholas James at 2015 ASCO Annual Meeting Inclusion criteria Presented By Nicholas James at 2015 ASCO Annual Meeting Outcome measures Presented By Nicholas James at 2015 ASCO Annual Meeting Accrual Presented By Nicholas James at 2015 ASCO Annual Meeting Docetaxel: Failure-free survival Presented By Nicholas James at 2015 ASCO Annual Meeting Docetaxel: Survival Presented By Nicholas James at 2015 ASCO Annual Meeting Zoledronic acid + docetaxel: Failure-free survival Presented By Nichol